Claims for Patent: 6,090,796

Summary for Patent: 6,090,796

Title:	Pharmaceutical composition for inhibiting the growth of cancers
Abstract:	This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains N-phosphonoglycine derivatives which are systemic herbicides in combination with chemotherapeutic agents for treatment of cancers and tumors. N-phosphonoglycine derivatives can be used to treat viral infections, particularly herpes infections. Optionally potentiators can be included.
Inventor(s):	Camden; James Berger (West Chester, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	09/220,914
Patent Claims:	1. A pharmaceutical composition for treating cancers or tumors or viral infections comprising a pharmaceutically acceptable carrier and a safe and effective amount of a chemotherapeutic agent and a safe and effective amount of an N-phosphonoglycine derivative of the formula: ##STR4## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxyl up to 12 carbon atoms, lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidinyl, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl; and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl; and certain salts of these compounds, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, acetate, salicylate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline. 2. A pharmaceutical composition according to claim 1 comprising a pharmaceutically acceptable carrier and a safe and effective amount of a N-(phosphonomethyl) glycine or an isopropyl amine salt thereof. 3. A pharmaceutical composition according to claim 1 wherein said salts are selected from the group consisting of hydrochloride, acetate, salicylate, lower alkyl amine and mixtures thereof. 4. A pharmaceutical composition according to claim 1 wherein said chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, and Plicamycin. 5. A pharmaceutical composition according to claim 4 wherein said chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Cytarabine, Floxuridine, Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin, Cyctrabine, and Fludarabine. 6. A pharmaceutical composition according to claim 4 which further comprises a potentiator. 7. A method of treating cancer in warm blooded mammals comprising administering a safe and effective amount of a pharmaceutical composition comprising a chemotherapeutic agent and an N-phosphonoglycine derivative of the formula: ##STR5## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxy up to 12 carbon atoms, lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidinyl, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl; and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl; and certain salts of these compounds, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, salicylate, acetate, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol, amine and aniline. 8. A method of treating cancer in warm blooded mammals according to claim 7 comprising administering a safe and effective amount of a N-(phosphonomethyl) glycine. 9. A method according to claim 8 wherein from about 2 mg/kg body weight to about 400 mg/kg of said N-(phosphonomethyl) glycine is administered. 10. A method according to claim 7 wherein said chemotherapeutic agent is selected from the group consisting of DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents, Asparaginase and hydroxyurea. 11. A method according to claim 10 wherein said chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, and Plicamycin. 12. A method according to claim 11 wherein said chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Cytarabine, Floxuridine, Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin, Cyctrabine, and Fludarabine. 13. A method according to claim 12 wherein said N-phosphonoglycine is a N-(phosphonomethyl) glycine isopropyl amine salt. 14. A unit dosage composition for treating tumors or viral infections comprising a safe and effective amount of a chemotherapeutic agent, an N-phosphonoglycine derivative of the formula: ##STR6## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxyl up to 12 carbon atoms, lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidinyl, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl, and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl; and certain salts of these compounds, which salts are selected from the group consisting of the Group I and II metals having an atomic number of up to 30, hydrochloride, pyridine, ammonium, lower aliphatic hydrocarbon amine, lower alkanol amine and aniline, and a pharmaceutically acceptable carrier. 15. A unit dosage composition according to claim 14 wherein said N-phosphonoglycine is N-(phosphonomethyl) glycine or a lower alkyl amine salt thereof. 16. A unit dosage composition according to claim 14 wherein said salts are selected from the group consisting of hydrochlorides, acetates, salicylates, and mixtures thereof. 17. A safe and effective treatment for viral infections comprising administering a safe and effective amount of a pharmaceutical composition comprising an N-phosphonoglycine derivative of the formula: ##STR7## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxy up to 12 carbon atoms, lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidinyl, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl; and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl; and a safe and effective amount of a potentiator. 18. A treatment according to claim 17 wherein said N-phosphonoglycine is administered orally or enterically or intravenously. 19. A treatment according to claim 17 wherein said N-phosphonoglycine is administered in a solid form. 20. A treatment according to claim 19 wherein said solid form includes a carrier selected from the group consisting of lactose, sucrose, gelatin and agar. 21. A treatment according to claim 20 wherein from about 15 mg/kg to about 150 mg/kg of said N-phosphonoglycine is administered. 22. A treatment according to claim 17 wherein said potentiator is procodazole. 23. A unit dosage composition for inhibiting the growth of tumors comprising a safe and effective amount of a systemic herbicide, a fungicide and a chemotherapeutic agent. 24. A unit dosage composition according to claim 23 which additionally comprises a potentiator. 25. A safe and effective treatment for herpes viral infections comprising administering a safe and effective amount of a pharmaceutical composition comprising an N-phosphonoglycine derivative of the formula: ##STR8## wherein X is selected from the group consisting of hydroxyl, alkoxy or chloroxy up to 12 carbon atoms, lower alkenoxy, cyclohexyloxy, morpholino, pyrrolidinyl, piperidino and NHR'; Y and Z each independently selected from hydrogen and lower alkyl; and R is selected from the group consisting of hydrogen, formyl, acetyl, benzoyl, nitrobenzoyl and chlorinated benzoyl; and R' is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, cyclohexyl, phenalkyl of up to 8 carbon atoms, phenyl, chlorinated phenyl and anisyl. 26. A treatment according to claim 25 wherein said N-phosphonoglycine is N-(phosphonomethyl)glycine or a lower alkyl amine salt thereof.

Details for Patent 6,090,796

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2015-04-12